Page 10 - reflections_newsletter
P. 10
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #11 2026
aggressive reductions in cholesterol did not come at the cost of patient safety; no significant between-group differences in the
incidence of serious safety events or adverse events leading to the discontinuation of the drug were found. Dyslipidaemia
Key subgroup analyses for the primary efficacy endpoints (3-point MACE)
CI, confidence interval; LDL, low-density lipoprotein; MACE, major adverse cardiovascular event.
In conclusion, adding a PCSK9i to baseline lipid-lowering
therapy provides significant, long-term CV benefits for patients
earlier on the atherosclerotic risk continuum. Aggressively
lowering LDL-C with evolocumab can safely and effectively
prevent first major CV events in high-risk patients with
atherosclerosis or diabetes before an MI or stroke ever occurs.
CLICK HERE
LISTEN TO DR. NANETTE KASS
WENGER DISCUSS WITH AUTHOR
DR. ERIN A. BOHULA THE VESALIUS-CV
TRIAL: EFFECT OF EVOLOCUMAB IN
CLICK HERE PATIENTS AT CV RISK WITHOUT PRIOR
FOR THE LINK TO FULL ARTICLE MI OR STROKE (9 MIN)
TABLE OF CONTENTS
